Emyria has been accepted into the prestigious National Institute of Neurological Disorders and Stroke (NINDS) Preclinical Screening Platform for Pain (PSPP) program.
The program is part of the U.S. National Institutes of Health HEAL Initiative®, and will evaluate our proprietary formulations of Ultra-Pure cannabinoids for suitability as pain treatments.
It’s another exciting step for our US-based preclinical programs and journey to US-FDA registration.
Read more: Emyria accepted into National Institutes of Health Program | Emyria Limited Investor Hub
